MMIRF MedMira Inc featured news, full reports, and detailed charts
MedMira Inc (MMIRF/MMIRF.PK) Wrap Up:
MedMira, Inc. engages in the development, manufacture, and marketing of rapid diagnostic products. The company?s products include HIV testing products, such as Reveal G3 Rapid HIV-1 Antibody Test, MedMira Rapid HIV Test, MiraWell Rapid HIV Test, and MiraCare Rapid HIV Antibody Test to detect antibodies to HIV in human serum, plasma, or whole blood. It also offers hepatitis testing products, including MiraWell Rapid HBV Test to detect hepatitis B virus (HBV) in serum, plasma, or whole blood; and MiraWell Rapid HCV Test to detect hepatitis C virus (HCV) in serum, plasma, or whole blood. In addition, the company provides the Multiplo product line for simultaneous detection of multiple diseases. Its Multiplo product line comprises Multiplo Rapid HIV/HCV Antibody Test for the simultaneous detection of infection with HIV and /or HCV; and Multiplo Rapid HBV/HIV/HCV Antibody Test for the simultaneous detection of antibodies against HBV, HIV, and/or HCV in serum, plasma, or whole blood. Further, MedMira, Inc. offers MedMira Rapid H. pylori Antibody Test for detecting antibodies specific to helicobacter pylori from serum or plasma; and MiraWell Rapid H. pylori Test to detect H. pylori antibodies in serum, plasma, or whole blood produced in response to H. pylori infection. It sells its rapid tests to various sectors of the healthcare industry, including laboratories, hospitals, point-of-care facilities, governments, and public health agencies through a network of medical distributors worldwide. The company was founded in 1994 and is headquartered in Halifax, Canada.www.medmira.com
Founded in 1994
MedMira Inc (MMIRF:Pink OTC Markets Inc)
LAST $0.05 USD
CHANGE TODAY -0.0017 -3.09%
VOLUME 10.0K
As of 10:35 AM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of MedMira Inc (MMIRF)
|
OPEN
$0.05
|
PREVIOUS CLOSE
$0.06
|
|
|
DAY HIGH
$0.05
|
DAY LOW
$0.05
|
|
|
52 WEEK HIGH
06/9/09 - $0.09
|
52 WEEK LOW
03/9/09 - $0.01
|
|
|
MARKET CAP
8.6M
|
AVERAGE VOLUME 3 mo
8.0K
|
|
|
DILUTED EPS TTM
--
|
SHARES OUTSTANDING
161.5M
|
|
|
MMIRF Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
MMIRF Top Compensated Officers
Mr. Hermes Chan
Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: C$172.2K
Mr. Richard Van Maanen
Vice President of Global Business Development
Age: 49
Total Annual Compensation: C$132.0K
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for MedMira Inc (MMIRF)
MedMira and Triplex to Launch Five New Rapid Tests in Mainland China and Hong Kong for Infectious Diseases, STDs, and Drugs of Abuse
08/25/2009
MedMira Inc. announced that it is expanding its product line with strategic partner, Triplex International Biosciences Co. Ltd. (Triplex), in Mainland China and Hong Kong. The partners are moving forward with SFDA regulatory submissions and subsequent market launch for rapid tests under the Multiplo brand including the HBV/HIV/HCV rapid test and combination tests for HIV and syphilis and HIV and tuberculosis. MedMira's rapid H. Pylori test, which detects a bacteria linked to the development of stomach cancer, will also be submitted for approval and launched into the market as part of this expanded distribution agreement. Triplex is currently the exclusive distributor for MedMira's rapid HIV test in this market. MedMira has also developed, in collaboration with Triplex, the single and multiple rapid tests for drugs of abuse such as amphetamines, methamphetamines, morphine, barbital, benzodiazepine, cocaine, THC, and ketamine. The multiple test can detect up to five of these drugs in just a few drops of urine. These new products will answer the demand for faster, more streamlined drug testing to combat the growing problem of drug abuse among the youth population in Hong Kong and Mainland China.
MedMira Introduces Expanded Multiplo(TM) Product Line at US Military Conference
08/10/2009
MedMira Inc. announced the introduction of new Multiplo(TM) rapid tests at the US Military's Advanced Technology Applications for Casualty Combat Care (ATACCC) Conference. The company is launching several new combination rapid tests for infectious and tropical diseases, and sexually transmitted diseases at the ATACCC Conference. Specifically these new tests will be used to diagnose disease such as HIV, Hepatitis B and C, syphilis, malaria, and Dengue fever in various combinations. The expanded Multiplo(TM) line also includes monitoring capabilities for vaccination effectiveness, applicable in military pre-deployment screening, public health vaccination programs, and vaccine development trials. Employing MedMira's distinctive and patented rapid flow-through technology, many of these new Multiplo(TM) tests will be the first of their kind in the diagnostics industry. The technology's unique advantages are multiple instant results on one test cartridge as well as the ease with which new test combinations can be geared up for full commercialization.
MedMira Inc. Reports New Product Sales in Bulgaria, Chile and Colombia
07/29/2009
MedMira Inc. announced that it has received new product sales orders from customers in several global markets, including Bulgaria, Chile, and Colombia. Bulgaria and Chile are new markets for MedMira, with orders and advance deposits received earlier this month from distributors in both countries. In Bulgaria, the Company's rapid HIV tests will fulfill a successful government tender bid and be used in a public health testing program. The company is working with its regional sales partner in Colombia to continue increasing rapid HIV test sales and pursuing new opportunities to introduce other MedMira rapid tests to these markets. MedMira's Colombian distributor was also successful in winning a government contract for rapid HIV tests.
MMIRF Competitors
| Company | Last | Change |
| Calypte Biomedical Corp | $0.01 USD | +0.002 |
| Chembio Diagnostics Inc | $0.34 USD | +0.025 |
| OraSure Tech Inc | $4.15 USD | -0.03 |
| StatSure Diagnostic Systems Inc | $0.06 USD | 0.00 |
| Trinity Biotech PLC | $4.07 USD | -0.12 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | MMIRF | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 5.8x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
MMIRF |
||
|
MMIRF transactions
| Type Date |
Target |
|
Private Placement
October 7, 2009 |
-- |
More Recent News About MedMira Inc
More news for MMIRF
MedMira and Swiss Investor Andurja Complete $2 Million in Equity Investment
HALIFAX, Nov. 9 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology and solutions, Andurja AG (Andurja), a Swiss investment company based in Lucerne, Switzerland announced today the completion of a CDN$2 million equity investment from Andurja to MedMira initiated on October 7, 2009. Andurja's owner Mr. Urs Meile is the controlling and majority shareholder of Vitest AG (Vitest), MedMira's business development partner in Europe and Africa. Under the terms of the deal Andurja acquired 40,000,000 equity units at $0.05 per unit. Each equity unit consists of one common share and one common share purchase warrant. Each full warrant entitles Andurja to purchase one common share of MedMira at $0.06 per share for the first year period while the second and third year are exercisable for one common share at a price of $0.10 per common share. The common shares are subject to a four month hold period that expires on March 4, 2010. With the completion of this transaction, Andurja now owns 19.85% of common shares of MedMira and will take a seat on the Company's Board of Directors.About Andurja AG/Vitest AGAndurja AG is a holding company of Vitest AG. Vitest AG is a privately held company based in Wollerau, Switzerland (www.vitest.ch) with a corporate subsidiary in Germany (Vitest GmbH) and South Africa (Vitest Southern Africa Ply). Vitest is the manufacturer/distributor of medical rapid tests and known well for their high quality products. The company provides doctors offices, clinics, private companies, NGOs and government institutions with innovative rapid tests. With the introduction o...Click here to read the whole Article (external link)
MedMira Rapid HIV Test Now Classified as Medical Device in China, Increasing Revenue and Sales Opportunities
HALIFAX, Sept. 24 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology and solutions, announced today that the Company's rapid HIV test approval has been renewed and is now classified as medical device in China. The regulatory license for MedMira's rapid HIV test, issued by China's State Food and Drug Administration (SFDA), was successfully renewed and re-classified as part of the ongoing healthcare reforms taking place in the country. As a regulated medical device, MedMira's rapid HIV test can be used in new and growing healthcare sectors including community diagnostic centers and mobile out-reach clinics."Similar to the US Food and Drug Administration's medical device regulations, this new classification allows MedMira to overcome a major hurdle in accessing the lucrative China market and we make another step forward in our long term business development plan for the Asia Pacific region," said Hermes Chan, CEO, MedMira Inc. "Local manufacturing is in place, our strategic sales and distribution partner, Triplex, is now up and running, and new markets are open to us with this new classification. With all of these favorable market conditions aligned and a shortened sales cycle we are now positioned to recognize an increase in revenue from rapid HIV tests sales in China in the coming quarters."Classified as a drug product by the country's regulators since its initial market entry in 2004, MedMira had experienced a number of complex market barriers in selling its rapid HIV test in large volumes throughout China. The new medical device classification means greater flexibility in regulatory guidelines, making it logistically easier to sell the rapid HIV test in all regions and all healthcare sectors in China."We are exploring every sales opportunity for MedMira's ra...Click here to read the whole Article (external link)
MedMira Announces Completion of Equity Line Draw Down
HALIFAX, Sept. 11 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology and solutions, announced today that it has completed the draw down against its equity line of credit with YA Global Investments LP which was announced on August 21, 2009. MedMira will use this capital to support new and ongoing sales and business development action plans. Under the terms negotiated in the equity line, YA Global Investments has purchased 2,604,639 common shares from MedMira at an average price of $ 0.0576 which is 96.5% of the daily volume weighted average price ("VWAP") over a 10 day pricing period, beginning on August 24, 2009 and ending on September 4, 2009 for net proceeds of $142,500.00 representing the draw down amount ($150,000.00) less a 5% utilization fee. The shares are not subject to a hold period.About MedMiraMedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global markets. MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.This news release contains forward-looking statements, which involve risk and uncertainties and...Click here to read the whole Article (external link)
MedMira and Triplex to Launch Five New Rapid Tests in Mainland China and Hong Kong for Infectious Diseases, STDs, and Drugs of Abuse
HALIFAX, Aug. 25 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology and solutions, announced today that it is expanding its product line with strategic partner, Triplex International Biosciences Co., Ltd. (Triplex), in Mainland China and Hong Kong. The partners are moving forward with SFDA regulatory submissions and subsequent market launch for rapid tests under the Multiplo brand including the HBV/HIV/HCV rapid test and combination tests for HIV and syphilis and HIV and tuberculosis. MedMira's rapid H. Pylori test, which detects a bacteria linked to the development of stomach cancer, will also be submitted for approval and launched into the market as part of this expanded distribution agreement. Triplex is currently the exclusive distributor for MedMira's rapid HIV test in this market.MedMira has also developed, in collaboration with Triplex, the single and multiple rapid tests for drugs of abuse such as amphetamines, methamphetamines, morphine, barbital, benzodiazepine, cocaine, THC, and ketamine. The multiple test can detect up to five of these drugs in just a few drops of urine. These new products will answer the demand for faster, more streamlined drug testing to combat the growing problem of drug abuse among the youth population in Hong Kong and Mainland China. According sources in Hong Kong, drug abuse among those under 21 has increased by 57% in the past four years. Local authorities are stepping up efforts to reverse the trend and battle the growing use of ketamine in particular, including random school-based drug tests."Expanding our product line with Triplex at this time is a very good opportunity for us to meet the increasing demand for advanced rapid diagnostics for drugs of abuse and other initiatives being implemented as China's new healthcare system ...Click here to read the whole Article (external link)
MedMira Announces Draw Down of Equity Line
HALIFAX, Aug. 21 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology and solutions, announced today that it has submitted a draw down notice for $150,000 to YA Global Investments LP against its equity line of credit. The capital available through the draw down on the equity line of credit enables MedMira to support its ongoing global sales and business development action plans. Under the terms negotiated in the equity line, YA Global Investments LP will purchase common shares from MedMira at a price to be calculated based on 96.5% of the daily volume weighted average price ("VWAP") over a 10 day pricing period, beginning on August 24, 2009. The settlement date is September 4, 2009. The issuance of the MedMira common shares with respect to this draw down is subject to the approval of the TSX Venture Exchange.About MedMiraMedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global markets. MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.This news release contains forward-looking statements, which involve risk and un...Click here to read the whole Article (external link)
Would you like to leave a comment about MedMira Inc MMIRF/MMIRF.PK
Find out what social network information about MedMira Inc are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides MedMira Inc there is more great information available at Realpennies.com